Beste apotheek van Nederland

Price D E, Cooksey G, Jehu D et al. The management of
impotence in diabetic men by vacuum tumescence therapy.
Diabet Med 1991;8(10):964-967.
Rodilla F, Fuentes M D, Chuan P et al. Penile self-injection for
impotence in patients after radical cystectomy. Journal of
Clinical Pharmacy & Therapeutics 1994;19(6):359-360.
Rodrigues M, Granegger S, O'Grady J et al. Accumulation of
platelets as a key mechanism of human erection. A scintigraphic
study in patients with erectile dysfunction receiving
intracavernous injection of PGE1, papaverine/phentolamine.
Advances in Experimental Medicine & Biology 1997;43379-82.
Schouman M, Lacroix P, Amer M. Suppression of prostaglandin
E1-induced pain by dilution of the drug with lidocaine before
intracavernous injection. Br J Urol 1992;148(4):1266
Sparwasser C, Treiber U, Bahren W et al. Postoperative erectile
dysfunction; evaluation and treatment with intracavernous
vasoactive injections. Progress in Clinical & Biological
Research 1991;370349-354.
Stief C G, Holmquist F, Djamilian M et al. Preliminary results
with the nitric oxide donor linsidomine chlorhydrate in the
treatment of human erectile dysfunction. Br J Urol
1992;148(5):1437-1440.
Stief C G, Wetterauer U, Schaebsdau F H et al. Calcitonin-generelated
peptide: a possible role in human penile erection and its
therapeutic application in impotent patients. Br J Urol
1991;146(4):1010-1014.
Vickers M A, De Nobrega A M, Dluhy R G. Diagnosis and
treatment of psychogenic erectile dysfunction in a urological
setting: Outcomes of 18 consecutive patients. Br J Urol
1993;149(5 SUPPL.):1258-1261.
Weiss J N, Ravalli R, Badlani G H. Intracavernous
pharmacotherapy in psychogenic impotence. Urology
1991;37(5):441-443.
Observational injection study > or = to 6 months in
duration.
al-Juburi A Z, O'Donnell P D. Follow up outcome of
intracavernous papaverine. J Ark Med Soc 1990;86(10):383­
385.
Armstrong D K, Convery A G, Dinsmore W W. Reasons for
patient drop-out from an intracavernous auto-injection
programme for erectile dysfunction. Br J Urol 1994;74(1):99­
101.
Chang D W, Wood C G, Kroll S S et al. Cavernous nerve
reconstruction to preserve erectile function following non-nervesparing
radical retropubic prostatectomy: a prospective study.
Keisei Geka 2003;111(3):1174-1181.
Chen J, Godschalk M F, Katz P G et al. Incidence of penile pain
after injection of a new formulation of prostaglandin E1.[see
comment]. Br J Urol 1995;154(1):77-79.
Chen J, Godschalk M F, Katz P G et al. Combining
intracavernous injection and external vacuum as
treatment for erectile dysfunction.[see comment]. Br J
Urol 1995;153(5):1476-1477.
Cooper A J. Evaluation of I-C papaverine in patients
with psychogenic and organic impotence. Canadian
Journal of Psychiatry - Revue Canadienne de
Psychiatrie 1991;36(8):574-578.
Dhabuwala C B, Kerkar P, Bhutwala A et al.
Intracavernous papaverine in the management of
psychogenic impotence. Arch Androl 1990;24(2):185­
191.
Fedele D, Coscelli C, Cucinotta D et al. Management
of erectile dysfunction in diabetic subjects: results
from a survey of 400 diabetes centres in Italy.
Diabetes, Nutrition & Metabolism - Clinical &
Experimental 2001;14(5):277-282.
Fein R L. Classification of sexual dysfunction for
management of intracavernous medication-induced
erections.[see comment]. Br J Urol 1990;143(2):298­
301.
Fugl-Meyer A R, Lodnert G, Branholm I B et al. On
life satisfaction in male erectile dysfunction. Int J
Impot Res 1997;9(3):141-148.
Godschalk M, Gheorghiu D, Chen J et al. Long-term
efficacy of a new formulation of prostaglandin E1 as
treatment for erectile failure.. Br J Urol
1996;155(3):915-917.
Govier F E, McClure R D, Weissman R M et al.
Experience with triple-drug therapy in a
pharmacological erection program.[see comment]. Br
J Urol 1993;150(6):1822-1824.
Incrocci L, Hop W C, Slob A K. Visual erotic and
vibrotactile stimulation and intracavernous injection in
screening men with erectile dysfunction: a 3 year
experience with 406 cases. Int J Impot Res
1996;8(4):227-232.
Irwin M B, Kata E J. High attrition rate with
intracavernous injection of prostaglandin E1 for
impotency. Urology 1994;43(1):84-87.
Jiann B-P, Yu C-C, Su C-C. Impact of introduction of
sildenafil on other treatment modalities for erectile
dysfunction: A study of nationwide and local hospital
sales. Int J Impot Res 2004;16(6):527-530.
Kattan S A. The acceptance of satisfaction of Saudi
males to vasoactive autoinjection intracavernous
therapy, external negative pressure device and penile
prosthesis in the treatment of erectile dysfunction. Ann
Saudi Med 2002;22(3-4):149-152.
D-157